Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Conditions

Short Bowel Syndrome 2Pena Shokeir syndrome, type 1 2Hyperphagia 2

Interventions

Zoledronic Acid 23Bevacizumab 13nilotinib 12Docetaxel 12Paclitaxel 11Everolimus 11Letrozole 10Imatinib Mesylate 10Capecitabine 10Erlotinib Hydrochloride 9Drug Therapy 9Carboplatin 9pegfilgrastim 8enzalutamide 8Trastuzumab 7Oxycodone 7Nivolumab 7Imiquimod 7Gemcitabine 7Epoetin Alfa 7icotinib 6Rituximab 6Prednisone 6Pemetrexed 6Oxaliplatin 6Leuprolide 6Fulvestrant 6Diclofenac 6Dexamethasone 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × soybean oil, phospholipid emulsion × Clear all
NCT04555044 2023-12-27

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A)

Baxter Healthcare Corporation

Phase 4 Completed
101 enrolled 29 charts

Pena Shokeir syndrome, type 1, Hyperphagia, Short Bowel Syndrome

NCT02476994 2021-07-21

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion

Baxter Healthcare Corporation

Phase 4 Terminated
1 enrolled 4 charts

Pena Shokeir syndrome, type 1, Hyperphagia, Short Bowel Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡